By: JACOB TEITELBAUM, MD in Vitality 101.
A recent study by the Stanford University ME/CFS clinical practice is showing remarkable promise in treating chronic fatigue syndrome using the medication Abilify.
At high doses, Abilify blocks the brain transmitter dopamine, and is used as an antipsychotic. But at extremely low doses it actually augments dopamine function. It’s reminiscent of the medication low-dose naltrexone. At high doses naltrexone blocks narcotic effects. At low doses it’s very effective in treating pain and CFS symptoms.
In the new Stanford study, instead of the usual 15 to 30 mg dose of Abilify, participants were given 1/8 to 2 mg each morning. 75% of the 101 subjects responded well:
To read the rest of this story, click on the link below: